Abstract:Activation of the Nod-like receptor 3 (NLRP3) inflammasome is important for activation of innate immune responses, but improper and excessive activation can cause inflammatory disease. We previously showed that glycolysis, a metabolic pathway that converts glucose into pyruvate, is essential for NLRP3 inflammasome activation in macrophages. Here, we investigated the role of metabolic pathways downstream glycolysis – lactic acid fermentation and pyruvate oxidation—in activation of the NLRP3 inflammasome. Using pharmacological or genetic approaches, we show that decreasing lactic acid fermentation by inhibiting lactate dehydrogenase reduced caspase-1 activation and IL-1β maturation in response to various NLRP3 inflammasome agonists such as nigericin, ATP, monosodium urate (MSU) crystals, or alum, indicating that lactic acid fermentation is required for NLRP3 inflammasome activation. Inhibition of lactate dehydrogenase with GSK2837808A reduced lactate production and activity of the NLRP3 inflammasome regulator, phosphorylated protein kinase R (PKR), but did not reduce the common trigger of NLRP3 inflammasome, potassium efflux, or reactive oxygen species (ROS) production. By contrast, decreasing the activity of pyruvate oxidation by depletion of either mitochondrial pyruvate carrier 2 (MPC2) or pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) enhanced NLRP3 inflammasome activation, suggesting that inhibition of mitochondrial pyruvate transport enhanced lactic acid fermentation. Moreover, treatment with GSK2837808A reduced MSU-mediated peritonitis in mice, a disease model used for studying the consequences of NLRP3 inflammasome activation. Our results suggest that lactic acid fermentation is important for NLRP3 inflammasome activation, while pyruvate oxidation is not. Thus, reprograming pyruvate metabolism in mitochondria and in the cytoplasm should be considered as a novel strategy for the treatment of NLRP3 inflammasome-associated diseases.

Niclosamide activates the NLRP3 inflammasome by intracellular acidification and mitochondrial inhibition

A novel mechanism for NLRP3 inflammasome activation

Mechanistic basis for potassium efflux-driven activation of the human NLRP1 inflammasome

Chemical mitochondrial uncouplers share common inhibitory effect on NLRP3 inflammasome activation through inhibiting NFκB nuclear translocation

K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling

New mitochondrial DNA synthesis enables NLRP3 inflammasome activation

Cutting Edge: Nitric Oxide Inhibits the NLRP3 Inflammasome.

Nitric oxide inhibits the NLRP3 inflammasome

Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation

Small molecule inhibitor binds to NLRP3 and prevents inflammasome activation

Hexokinase dissociation from mitochondria promotes oligomerization of VDAC that facilitates NLRP3 inflammasome assembly and activation

Mechanistic basis for nigericin-induced NLRP1 inflammasome activation in human epithelial cells

NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners

Α7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation by Preventing Mitochondrial DNA Release

Dntp Catabolism is a Macrophage-Intrinsic Gatekeeper Preventing NLRP3 Inflammasome Hyperactivation

Orchestration of NLRP3 Inflammasome Activation by Ion Fluxes

Nitric Oxide Inhibits the NLRP3 Inflammasome (P1270)

Small molecule inhibitor binds to NOD-like receptor family pyrin domain containing 3 and prevents inflammasome activation

Distinct Molecular Mechanisms Underlying Potassium Efflux for NLRP3 Inflammasome Activation

Mitochondrial DNA in NLRP3 inflammasome activation

Initiation and perpetuation of NLRP3 inflammasome activation and assembly